This is a numbers-first look at Torrent Pharmaceuticals Ltd. (TORNTPHARM), covering income trends, margins, valuation, and shareholding.
Torrent Pharma Revenue Trend
The top line tells a positive story: Torrent Pharmaceuticals Ltd.'s revenue advanced 7.0% to ₹11,539 Cr in FY2025.
The 10-year revenue CAGR of 9.5% reflects steady — if not spectacular — top-line expansion from ₹4,653 Cr to ₹11,539 Cr.
In terms of scale, Torrent Pharmaceuticals Ltd.'s ₹11,539 Cr in annual revenue positions it as a major pharmaceuticals company.
Looking at the year-on-year numbers, Torrent Pharmaceuticals Ltd. has seen 8 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹11,539 Cr | +7.0% |
| FY2024 | ₹10,786 Cr | +11.6% |
| FY2023 | ₹9,665 Cr | +11.0% |
| FY2022 | ₹8,705 Cr | +8.7% |
| FY2021 | ₹8,005 Cr | — |
View Torrent Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Torrent Pharma Profitability
A 15.4% improvement in net profit took Torrent Pharmaceuticals Ltd.'s bottom line to ₹1,911 Cr in FY2025.
Net margin expanded to 16.6% in FY2025, up from 15.4% a year prior.
On an EPS basis, the company earned ₹56.47 (diluted) in FY2025 versus ₹48.94 in FY2024.
Is Torrent Pharma Undervalued
Using the P/E Ratio methodology, the calculated intrinsic value comes to ₹3,551.
Torrent Pharmaceuticals Ltd. shares are currently trading at ₹4,368.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹3,551 | 18.7% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Torrent Pharmaceuticals Ltd. with detailed assumptions →
Torrent Pharma Shareholding Pattern
Promoters continue to hold 68.3% of the company, unchanged over recent quarters.
On the foreign institutional side, the holding is 16.2% as of March 2026 — up from 16.1%.
The DII stake stands at 9.1% as of March 2026, versus 8.7% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 68.3% | 16.2% | 9.1% | 6.5% |
| Dec 2025 | 68.3% | 16.1% | 9.1% | 6.4% |
| Sep 2025 | 68.3% | 15.9% | 9.3% | 6.5% |
| Jun 2025 | 68.3% | 16.1% | 8.7% | 6.9% |
Track quarterly shareholding changes for Torrent Pharmaceuticals Ltd. →
Torrent Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹149.90B (down 0.5% YoY from ₹150.61B).
Top categories: Intangibles & Goodwill (30.0%), Property, Plant & Equipment (23.9%), Inventories (17.0%).
Of the ₹149.90B in liabilities and equity, 50.6% is shareholder equity, 21.4% is interest-bearing debt, and 28.0% is operating liabilities. Over the year, debt is down 20.4% and equity is up 10.7%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 6.86B |
| Receivables | 18.66B |
| Inventories | 25.41B |
| Property, Plant & Equipment | 35.77B |
| Investments | 435.70M |
| Intangibles & Goodwill | 44.91B |
| Other Assets | 17.85B |
| Category | Value |
|---|---|
| Equity | 75.91B |
| Short-term Debt | 18.65B |
| Long-term Debt | 13.38B |
| Trade Payables | 18.20B |
| Other Liabilities | 23.77B |
Torrent Pharma — The Bottom Line
To sum up Torrent Pharmaceuticals Ltd.'s financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹11,539 Cr in FY2025, up 7.0% year-over-year.
Long-term revenue has been compounding at 9.5% annually over 10 years.
The company is profitable, with a net margin of 16.6% and net income of ₹1,911 Cr.
The P/E Ratio model implies 18.7% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Torrent Pharmaceuticals Ltd..